文献速递创伤骨科关节外科

血管内皮生长因子通路促进小鼠胫骨植入物模型中的骨整合及CD31hiEMCNhi内皮扩增:一项动物研究

Vascular endothelial growth factor pathway promotes osseointegration and CD31hiEMCNhi endothelium expansion in a mouse tibial implant model: an animal study.
PubMed 文献 · Bone Joint J · 2019-01-01

该研究在小鼠胫骨植入物模型中通过药理学阻断血管内皮生长因子(VEGF)通路,探讨血管生成与骨生成的偶联关系。结果显示抗VEGFR治疗减少CD31hiEMCNhi内皮、增加OSX和OPN阳性成骨谱系细胞,并降低拉出测试最大负荷。结论认为VEGF通路通过影响CD31hiEMCNhi内皮形成调控骨科植入物骨整合中的血管生成与骨生成偶联。

要点

  • 抗VEGFR抗体处理组较对照组减少植入物周围骨CD31hiEMCNhi血管内皮。
  • 处理组在植入后两周和四周的植入物周围骨及植入物表面组织中有更多OPN阳性细胞。
  • 处理组在植入后两周植入物周围骨中有更多OSX阳性细胞,且拉出测试最大负荷较对照组降低。

核心结论

  • VEGF通路通过影响CD31hiEMCNhi内皮的形成,调控骨科植入物骨整合中血管生成与骨生成的偶联。

研究设计与样本

  • 动物实验:将植入物插入16周龄雌性C57BL/6小鼠右侧胫骨(n=38)。
  • 小鼠接受抗VEGFR-1抗体(25 mg/kg)和VEGFR-2抗体(25 mg/kg;n=19)或同型对照抗体(n=19)。

主要发现

  • 流式细胞术(每组n=4)显示抗VEGFR治疗组在植入后两周植入物周围骨的CD31hiEMCNhi血管内皮较对照组减少。
  • 免疫荧光(每组n=3)证实抗VEGFR治疗组CD31与内皮粘蛋白(EMCN)双阳性细胞减少。
  • 处理组在植入后两周植入物周围骨和四周植入物表面组织中OPN阳性细胞均较对照组多,两周植入物周围骨中OSX阳性细胞较对照组多。
  • 抗VEGFR治疗组拉出测试最大负荷较对照组降低(每组n=12,四周时检测)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: It is increasingly appreciated that coordinated regulation of angiogenesis and osteogenesis is needed for bone formation. How this regulation is achieved during peri-implant bone healing, such as osseointegration, is largely unclear. This study examined the relationship between angiogenesis and osteogenesis in a unique model of osseointegration of a mouse tibial implant by pharmacologically blocking the vascular endothelial growth factor (VEGF) pathway. MATERIALS AND METHODS: An implant was inserted into the right tibia of 16-week-old female C57BL/6 mice (n = 38). Mice received anti-VEGF receptor-1 (VEGFR-1) antibody (25 mg/kg) and VEGF receptor-2 (VEGFR-2) antibody (25 mg/kg; n = 19) or an isotype control antibody (n = 19). Flow cytometric (n = 4/group) and immunofluorescent (n = 3/group) analyses were performed at two weeks post-implantation to detect the distribution and density of CD31hiEMCNhi endothelium. RNA sequencing analysis was performed using sorted CD31hiEMCNhi endothelial cells (n = 2/group). Osteoblast lineage cells expressing osterix (OSX) and osteopontin (OPN) were also detected with immunofluorescence. Mechanical pull-out testing (n = 12/group) was used at four weeks post-implantation to determine the strength of the bone-implant interface. After pull-out testing, the tissue attached to the implant surface was harvested. Whole mount immunofluorescent staining of OSX and OPN was performed to determine the amount of osteoblast lineage cells. RESULTS: Flow cytometry revealed that anti-VEGFR treatment decreased CD31hiEMCNhi vascular endothelium in the peri-implant bone versus controls at two weeks post-implantation. This was confirmed by the decrease of CD31 and endomucin (EMCN) double-positive cells detected with immunofluorescence. In addition, treated mice had more OPN-positive cells in both peri-implant bone and tissue on the implant surface at two weeks and four weeks, respectively. More OSX-positive cells were present in peri-implant bone at two weeks. More importantly, anti-VEGFR treatment decreased the maximum load of pull-out testing compared with the control. CONCLUSION: VEGF pathway controls the coupling of angiogenesis and osteogenesis in orthopaedic implant osseointegration by affecting the formation of CD31hiEMCNhi endothelium. Cite this article: Bone Joint J 2019;101-B(7 Supple C):108-114.

来源:Bone Joint J,查看原文。版权归原作者所有。

引用

  1. Ji G, Xu R, Niu Y, et al. Vascular endothelial growth factor pathway promotes osseointegration and CD31hiEMCNhi endothelium expansion in a mouse tibial implant model: an animal study. Bone Joint J. 2019. PMID: 31256654. doi:10.1302/0301-620X.101B7.BJJ-2018-1473.R1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。